Antioxidant and anticholinesterase effects of rosemary (Salvia rosmarinus) extract: A double-blind randomized controlled trial

IF 1.7 Q2 Medicine

Advances in integrative medicine Pub Date : 2022-03-01 DOI:10.1016/j.aimed.2021.03.002

Fatemeh Dabaghzadeh , Mitra Mehrabani , Homa Abdollahi , Somayyeh Karami-Mohajeri

{"title":"Antioxidant and anticholinesterase effects of rosemary (Salvia rosmarinus) extract: A double-blind randomized controlled trial","authors":"Fatemeh Dabaghzadeh , Mitra Mehrabani , Homa Abdollahi , Somayyeh Karami-Mohajeri","doi":"10.1016/j.aimed.2021.03.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The present study was aimed at investigating the effect of <span><em>Salvia</em><span><em> </em><em>rosmarinus</em></span></span> (syn: <em>Rosmarinus officinalis</em><span><span> L.; rosemary) extract on acetyl cholinesterase (AChE) activity and </span>oxidative stress biomarkers in healthy volunteers.</span></p></div><div><h3>Method</h3><p><span>In a double-blind randomized controlled trial<span><span>, 50 healthy participants (21–25 years old) were divided into two groups: placebo (N = 25) and rosemary (N = 25). The rosemary and placebo groups respectively received rosemary (500 mg rosemary powder) and placebo capsules (500 mg starch powder) twice a day for one month. AChE activity, total </span>antioxidant capacity<span> (TAC), lipid peroxidation, and </span></span></span>protein carbonylation were determined in blood samples before and after the trial.</p></div><div><h3>Discussion</h3><p><span>Administration of 1000 mg of rosemary for 30 days significantly decreased AChE activity compared to AChE activity before rosemary treatment (</span><em>p</em> value<0.001) and also in the placebo group (p value<0.01). Notably, administration of rosemary considerably improved TAC (<em>p</em> value<0.01) and protein carbonylation (<em>p</em> value<0.05) compared to those values before rosemary treatment and in the placebo group. After administration of rosemary, no significant changes were observed in lipid peroxidation (p value>0.05) compared to that value before rosemary treatment and in the placebo group.</p></div><div><h3>Conclusion</h3><p>The findings indicated the inhibitory effect of rosemary on AChE activity and the improvement of non-enzymatic antioxidant defense system. The results may reinforce the use of rosemary as a potential antioxidant supplement. Further evaluations are recommended to find out the effectiveness of rosemary in patients with Alzheimer’s disease.</p></div>","PeriodicalId":7343,"journal":{"name":"Advances in integrative medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.aimed.2021.03.002","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in integrative medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212958821000215","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Objective

The present study was aimed at investigating the effect of Salvia rosmarinus (syn: Rosmarinus officinalis L.; rosemary) extract on acetyl cholinesterase (AChE) activity and oxidative stress biomarkers in healthy volunteers.

Method

In a double-blind randomized controlled trial, 50 healthy participants (21–25 years old) were divided into two groups: placebo (N = 25) and rosemary (N = 25). The rosemary and placebo groups respectively received rosemary (500 mg rosemary powder) and placebo capsules (500 mg starch powder) twice a day for one month. AChE activity, total antioxidant capacity (TAC), lipid peroxidation, and protein carbonylation were determined in blood samples before and after the trial.

Discussion

Administration of 1000 mg of rosemary for 30 days significantly decreased AChE activity compared to AChE activity before rosemary treatment (p value<0.001) and also in the placebo group (p value<0.01). Notably, administration of rosemary considerably improved TAC (p value<0.01) and protein carbonylation (p value<0.05) compared to those values before rosemary treatment and in the placebo group. After administration of rosemary, no significant changes were observed in lipid peroxidation (p value>0.05) compared to that value before rosemary treatment and in the placebo group.

Conclusion

The findings indicated the inhibitory effect of rosemary on AChE activity and the improvement of non-enzymatic antioxidant defense system. The results may reinforce the use of rosemary as a potential antioxidant supplement. Further evaluations are recommended to find out the effectiveness of rosemary in patients with Alzheimer’s disease.

查看原文本刊更多论文

迷迭香提取物的抗氧化和抗胆碱酯酶作用:一项双盲随机对照试验

目的研究迷迭香(鼠尾草)的抗氧化作用;迷迭香提取物对健康志愿者乙酰胆碱酯酶(AChE)活性和氧化应激生物标志物的影响。方法采用双盲随机对照试验，将50例21 ~ 25岁的健康受试者分为安慰剂组(N = 25)和迷迭香组(N = 25)。迷迭香组和安慰剂组分别服用迷迭香(500毫克迷迭香粉)和安慰剂胶囊(500毫克淀粉粉)，每天两次，持续一个月。在试验前后测定血液样本中的AChE活性、总抗氧化能力(TAC)、脂质过氧化和蛋白质羰基化。与迷迭香治疗前(p值<0.001)和安慰剂组(p值<0.01)相比，1000mg迷迭香治疗30天显著降低乙酰胆碱酯酶活性。值得注意的是，与迷迭香治疗前和安慰剂组相比，迷迭香治疗显著改善了TAC (p值<0.01)和蛋白质羰基化(p值<0.05)。迷迭香给药后，与迷迭香治疗前和安慰剂组相比，脂质过氧化无显著变化(p值>0.05)。结论迷迭香对乙酰胆碱酯酶活性有抑制作用，可改善非酶抗氧化防御系统。这一结果可能会加强迷迭香作为一种潜在的抗氧化剂补充剂的使用。建议进一步评估迷迭香对阿尔茨海默病患者的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in integrative medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

3.20

自引率

11.80%

发文量

审稿时长

15 weeks

期刊介绍： Advances in Integrative Medicine (AIMED) is an international peer-reviewed, evidence-based research and review journal that is multi-disciplinary within the fields of Integrative and Complementary Medicine. The journal focuses on rigorous quantitative and qualitative research including systematic reviews, clinical trials and surveys, whilst also welcoming medical hypotheses and clinically-relevant articles and case studies disclosing practical learning tools for the consulting practitioner. By promoting research and practice excellence in the field, and cross collaboration between relevant practitioner groups and associations, the journal aims to advance the practice of IM, identify areas for future research, and improve patient health outcomes. International networking is encouraged through clinical innovation, the establishment of best practice and by providing opportunities for cooperation between organisations and communities.